id: NEW:omega_3_pufa_supplementation_to_NEW:nafld_metabolic_profile
name: Omega-3 PUFA Supplementation â†’ NAFLD Metabolic Profile
from_node:
  node_id: NEW:omega_3_pufa_supplementation
  node_name: Omega-3 PUFA Supplementation
to_node:
  node_id: NEW:nafld_metabolic_profile
  node_name: NAFLD Metabolic Profile
direction: negative
category: biological
mechanism_pathway:
- 'Step 1: Omega-3 PUFAs (EPA and DHA) are incorporated into hepatocyte cell membranes
  and serve as substrates for anti-inflammatory mediator synthesis'
- 'Step 2: Omega-3 PUFAs activate peroxisome proliferator-activated receptors (PPARs),
  particularly PPAR-alpha, enhancing hepatic fatty acid oxidation'
- 'Step 3: Reduced hepatic lipogenesis and enhanced lipid metabolism lead to decreased
  triglyceride accumulation in the liver'
- 'Step 4: Improved hepatic lipid handling results in reduced hepatocellular injury,
  manifested as decreased ALT and AST levels'
- 'Step 5: Systemic lipid profile improvements occur with reductions in serum triglycerides,
  LDL cholesterol, and total cholesterol'
evidence:
  quality_rating: A
  n_studies: 15
  primary_citation: 'Tarique Aziz et al. 2024. Effectiveness of Omega-3 Polyunsaturated
    Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Cureus.'
  supporting_citations: []
description: Omega-3 PUFA supplementation improves metabolic profiles in NAFLD patients
  through multiple mechanisms including enhanced hepatic fatty acid oxidation, reduced
  lipogenesis, and anti-inflammatory effects. Meta-analysis of 15 studies demonstrated
  significant reductions in liver enzymes (ALT mean difference -2.12, AST mean difference
  -1.50) and improvements in serum lipid profiles including triglycerides, LDL, and
  total cholesterol. While impact on liver fat content remains uncertain, omega-3
  supplementation provides beneficial effects on metabolic parameters in NAFLD.
last_updated: '2025-12-02'
extraction_method: consolidated_batch_v3
quantitative_effects:
  effect_size:
    value: -2.12
    type: mean_difference
    ci_lower: -3.36
    ci_upper: -0.87
  p_value: null
  sample_size: null
moderators:
- name: Study type (human vs animal)
  direction: strengthens
  strength: moderate
  description: Animal models showed more consistent and significant reductions in
    hepatic enzymes including AST, ALT, and alkaline phosphatase compared to human
    studies
